drugset / Trial / NCT01379300

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

NCT01379300

Phase 1 Completed 42 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelTreatment

Summary

This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.

Timeline

Start
2011-05
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Subject Rivaroxaban Other / unclassified 20 mg Oral

Indications